NMS medicines list

NMS medicines list

Four conditions/therapy areas were selected to be included in the initial rollout of the New Medicine Service (NMS). These are:

  1. asthma and COPD;
  2. type 2 diabetes;
  3. antiplatelet/anticoagulant therapy; and
  4. hypertension.

The rationale for selection of the therapy areas/conditions was twofold: first, the evidence from the original proof of concept research, and secondly on the basis that these are areas where community pharmacists are best able to demonstrate the value of the service.

For each therapy area/condition, a list of medicines has been agreed. If a patient is newly prescribed one of these medicines then they will be eligible to receive the service, subject to the pharmacist being able to determine that the medicine is being used to treat one of the above conditions in circumstances where a medicine can be used to treat multiple conditions.

NMS Medicines List Factsheet


Click on a heading below for more information. 

Asthma and COPD

If a patient is newly prescribed a medicines listed in the chapters/sub-sections, detailed below, of the current edition of the British National Formulary (www.bnf.org) they will be eligible to receive NMS, subject to the pharmacist being able to determine the medicine is being used for asthma or COPD:

BNF Reference

BNF subsection descriptor

3.1.1 Adrenoceptor agonists
3.1.2 Antimuscarinic bronchodilators
3.1.3 Theophylline
3.1.4 Compound bronchodilator preparations
3.2 Corticosteroids
3.3 Cromoglicate and related therapy, leukotriene receptor antagonists and phosphodiesterase type-4 inhibitors

Type 2 diabetes

If a patient is newly prescribed a medicines listed in the chapters/sub-sections, detailed below, of the current edition of the British National Formulary (www.bnf.org) they will be eligible to receive NMS, subject to the pharmacist being able to determine the medicine is being used for Type 2 diabetes:

BNF Reference

BNF subsection descriptor

6.1.1.1

Short acting insulins (where the community pharmacist can determine that the medicine has been newly prescribed for a patient with Type 2 diabetes)

6.1.1.2

Intermediate and long acting insulins (where the community pharmacist can determine that the medicine has been newly prescribed for a patient with Type 2 diabetes)

6.1.2 Antidiabetic drugs

Antiplatelet/anticoagulant therapy

If a patient is newly prescribed a medicines listed in the chapters/sub-sections, detailed below, of the current edition of the British National Formulary (www.bnf.org) they will be eligible to receive NMS, subject to the pharmacist being able to determine the medicine is being used for antiplatelet/anticoagulant therapy:

BNF Reference

BNF subsection descriptor

2.8.2 Oral anticoagulants
2.9 Antiplatelet drugs

Hypertension

If a patient is newly prescribed a medicines listed in the chapters/sub-sections, detailed below, of the current edition of the British National Formulary (www.bnf.org) they will be eligible to receive NMS, subject to the pharmacist being able to determine the medicine is being used for hypertension:

BNF Reference BNF subsection descriptor
2.2.1 Thiazides and related diuretics
2.4 Beta-adrenoceptor blocking drugs (where the community pharmacist can determine that the medicine has been newly prescribed for a patient with hypertension)
2.5.1

Vasodilator antihypertensive drugs

2.5.2 Centrally acting antihypertensive drugs
2.5.4

Alpha-adrenoceptor blocking drugs (where the community pharmacist can determine that the medicine has been newly prescribed for a patient with hypertension)

2.5.5

Drugs affecting the renin-angiotensin system (where the community pharmacist can determine that the medicine has been newly prescribed for a patient with hypertension)

2.6.2

Calcium-channel blockers (where the community pharmacist can determine that the medicine has been newly prescribed for a patient with hypertension)

Related resources

PSNC Briefing 033/15: Services Factsheet – NMS Medicines List (July 2015)
This Briefing outlines the requirements for patients to be eligible to receive the NMS service. 



Latest Services and Commissioning news

View more Services and Commissioning news >